With a price/sales ratio of 6.81, Adma Biologics Inc has a higher such ratio than 84.1% of stocks in our set.
Revenue growth over the past 12 months for Adma Biologics Inc comes in at 118.68%, a number that bests 95.37% of the US stocks we're tracking.
Adma Biologics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -72.19%, greater than the shareholder yield of merely 6.74% of stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Adma Biologics Inc are DPW, ELGX, TTMI, NESR, and SWM.
ADMA Biologics, Inc. develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The company was founded in 2004 and is based in Ramsey, New Jersey.
At this time, I would like to introduce Mr. Sam Martin, Managing Director at Argot Partners, ADMA's Investor Relations firm. Welcome everyone, and thank you for joining us this afternoon to discuss ADMA Biologics' financial results for the first quarter 2020.
The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19, is rapidly building momentum. Its membership has expanded globally to include 10 plasma companies, and now also includes global organizations from outside the plasma industry who are providing vital support to encourage more people to donate plasma.